Visugromab in Cachexia International Trial

Study acronym: VINCIT
StatusRecruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 71 → 74 locations
    • Eligibility criteria expanded, about 3 words
  2. Trial sites expanded: 65 → 71 locationsv10
  3. Trial sites expanded: 56 → 65 locationsv9
  4. Trial sites expanded: 35 → 56 locationsv8
  5. Study sites: 34 to 35v7
  6. Trial sites expanded: 7 → 34 locationsv6
  7. Trial sites expanded: 1 → 7 locations
    • Start date changed from estimate of Apr 2026 to Apr 16, 2026
    v5
  8. Start date: Jan 2026 to Apr 2026v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 2026 to Jan 2026
    v3
  10. Interventions: Placebo (Drug), Visugromab (CTL-002) (Drug) to Placebo (Drug), Visugromab (CTL-002) (Drug), Visugromab (CTL-002) (Drug), Visugromab (CTL-002) (Drug)v2
  11. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CatalYm GmbH
6 trials monitored
See 1 trial at risk
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Trial Details
NCT Number NCT07112196
Lead Sponsor CatalYm GmbH
Conditions
(from sponsor)		 Cancer-associated Cachexia
Related terms Anorexia, Cachexia, Neoplasms, Weight Loss
Enrollment 518 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov